Community/Retail

Officials with Novo Nordisk have announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 16-0, supporting the approval of once-weekly semaglutide to improve glycemic control in adults with type 2 diabetes.

FDA OKs Generic Emend

By

Patients undergoing moderately emetogenic chemotherapy may use the product, in combination with other antiemetic medicines, for the prevention of delayed nausea and vomiting.